← 返回

以 HLA-C*07:01 限制性 T 细胞受体靶向黑色素瘤相关抗原 CSPG4

英文原题:Targeting the melanoma-associated antigen CSPG4 with HLA-C*07:01-restricted T-cell receptors.

查看英文原题

Targeting the melanoma-associated antigen CSPG4 with HLA-C*07:01-restricted T-cell receptors.

PubMed 2023/10/02(内容时间) Front Immunol Q1 · IF 7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

表达 11C/73 和 2C/165 的 T 细胞能够特异且高效地识别 CSPG4 + HLA-C*07:01 + 癌细胞,这值得对这些 TCR 进行进一步的临床前和临床评估。

研究思路结论见上方概要

从两个CSPG4反应性T细胞克隆(11C/73和2C/165)中分离出受高流行率HLA-C*07:01等位基因限制的TCR,并将各自的αβTCR对通过逆转录病毒在CRISPR/Cas9编辑的TCR敲除T细胞中表达以进行功能测试。我们还以交叉方式组合了源自11C/73和2C/165的α和β TCR链,以评估半链优势。鉴定了CSPG4+黑色素瘤、胶质母细胞瘤和肺癌细胞系,如果为阴性,则通过逆转录病毒转导HLA-C*07:01。

功能测试证实,从亲本T细胞克隆中获取的αβTCR能特异性识别CSPG4 + HLA-C*07:01 + 靶细胞,交叉TCR构建体2Cα-11Cβ也部分具有此功能。然而,尽管11Cα-2Cβ组合表面表达高,却不具备功能性。

展开英文摘要原文

The TCRs of two CSPG4-reactive T-cell clones (11C/73 and 2C/165) restricted by the highly prevalent HLA-C*07:01 allele were isolated and the respective αβTCR pairs were retrovirally expressed in CRISPR/Cas9-edited TCR-knockout T cells for functional testing. We also combined alpha and beta TCR chains derived from 11C/73 and 2C/165 in a cross-over fashion to assess for hemichain dominance. CSPG4 + melanoma, glioblastoma and lung cancer cell lines were identified and, if negative, retrovirally transduced with HLA-C*07:01.

Functional tests confirmed specific recognition of CSPG4 + HLA-C*07:01 + target cells by the αβTCR retrieved from the parental T-cell clones and in part also by the cross-over TCR construct 2Cα-11Cβ. Despite high surface expression, the 11Cα-2Cβ combination, however, was not functional. DISCUSSION: Collectively, 11C/73- and 2C/165-expressing T cells specifically and efficiently recognized CSPG4 + HLA-C*07:01 + cancer cells which warrants further preclinical and clinical evaluation of these TCRs.

论文信息

作者
Kropp KN、Fatho M、Huduti E、Faust M、Lübcke S、Lennerz V、Paschen A、Theobald M
单位
Internal Medicine III, University Cancer Center (UCT), Research Center for Immunotherapy (FZI), University Medical Center (UMC) of the Johannes Gutenberg University and German Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz, Mainz, Germany.Germany
文献类型
非美国政府资助研究
期刊
Frontiers in immunology2023
原文标识
PubMed 37849763 · DOI 10.3389/fimmu.2023.1245559